Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cotton flower total flavonoids (TFG) is a botanical drug candidate extracted from the flowers of *Gossypium herbaceum* L. (Levant cotton), a plant traditionally used in Uighur medicine in the Xinjiang region of China. Developed by the Xinjiang Institute of Ecology and Geography of the Chinese Academy of Sciences, TFG is primarily being investigated for the treatment of Alzheimer's disease and other forms of cognitive impairment. The extract is a complex mixture of flavonoid compounds, including quercetin, isoquercitrin, and rutin, which collectively provide neuroprotective benefits. Its mechanism of action is multi-targeted, involving the inhibition of acetylcholinesterase (AChE) to enhance cholinergic signaling, the reduction of amyloid-beta (Aβ) plaque formation and aggregation, and the mitigation of oxidative stress and neuroinflammation. TFG has advanced into Phase 2 clinical trials in China, where it is being evaluated for its ability to improve memory and cognitive function in patients with mild-to-moderate Alzheimer's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cotton flower total flavonoids.